Improving medication adherence research reporting: ESPACOMP Medication Adherence Reporting Guideline (EMERGE)

Geest, Sabina De; Zullig, Leah L.; Dunbar‐Jacob, Jacqueline; Hughes, Dyfrig; Wilson, Ira B.; Vrijens, Bernard

doi:10.1177/1474515119830298

Cited by 19 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concepts of implementation and adherence presented in this study align with other standardized taxonomies including the taxonomy provided by the Ascertaining Barriers to Compliance (ABC) project team, as well as adherence reporting guidelines that utilize ABC taxonomy such as the ESPACOMP Medication Adherence Reporting Guideline (EMERGE). 43 , 44 We operationalized the concepts using the terminology defined by ISPOR, which places an enhanced focus on refill data. 44 This was deemed to be appropriate, as metrics included for adherence analysis in this study required multiple fills of tafamidis prescriptions.…”

Section: Discussionmentioning

confidence: 99%

Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database

Roy¹,

Peterson²,

Marchant³

et al. 2022

PPA

View full text Add to dashboard Cite

Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious, underrecognized condition, which leads to heart failure and early mortality if left untreated. Until recently, heart transplantation was the only treatment for ATTR-CM. Regulatory approval of tafamidis transformed treatment for patients. In the phase 3 Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT), which established the safety and efficacy of tafamidis, medication adherence was high with 97.2% of patients taking ≥80% of scheduled doses. Evidence of real-world adherence to cardiology drugs demonstrates low adherence and suboptimal outcomes; however, real-world adherence to tafamidis has not been investigated. The main objective of this study was to describe adherence patterns of patients filling tafamidis in the Symphony Health database. Methods This retrospective analysis of the Symphony Health Solutions claims database used secondary adherence measures, including modified medication possession ratio (MPRm), days between fills adherence rate, and compliance rate, to assess adherence patterns of 2020 patients filling tafamidis free acid 61-mg capsules or tafamidis meglumine 4x20-mg capsules from June 1, 2019 to August 31, 2020. Results Patients receiving a tafamidis formulation had characteristics consistent with the expected patient population; 71.6% were aged 75–84 years, 83.2% were male, and the highest proportion resided in the Northeast region (30.5%) of the United States. Adherence for tafamidis was high, as 75% to 100% of the patients across subgroups met or exceeded the commonly defined adherence threshold of 80%. Median number of refills ordered and received was six refills per patient. Most patients received refills with no gap (n=1633) or a gap <30 days (n=1267/1317 patients). Adherence was high across follow-up time, sex, and age subgroups. Adherence varied by geographic region, with the Northeast being significantly higher than the Midwest (mean MPRm 94.41% vs 88.21%, p=0.0007). Conclusion These results provide evidence that real-world adherence to tafamidis in patients with ATTR-CM is high.

show abstract

Section: Discussionmentioning

confidence: 99%

Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database

Roy¹,

Peterson²,

Marchant³

et al. 2022

PPA

View full text Add to dashboard Cite

show abstract

“…The MEMS (Aardex Group, Vise, Belgium) cap was used to quantify the three domains (initiation, implementation, and persistence) of rifaximin adherence. The medication adherence taxonomy as described by Vrijens and colleagues (2012) and medication adherence reporting guidelines (De Geest et al, 2019) was used to assess objective adherence. The initiation adherence parameter was defined as the number of days from when the cap was placed on the rifaximin medication bottle to when the first container was opened by the participant.…”

Section: Methodsmentioning

confidence: 99%

“…The daily dose was calculated as the number of days the participant opened the container at least three times a day for 14 days. The persistence adherence parameter was defined as the number of days from the first dose to the last dose (De Geest et al, 2019). The participants’ health care provider established the treatment plan and provided the rifaximin prescription.…”

Section: Methodsmentioning

confidence: 99%

Adherence to Short-course Pharmacotherapy in Adults with Irritable Bowel Syndrome

et al. 2019

View full text Add to dashboard Cite

Irritable Bowel Syndrome (IBS), characterized by abdominal pain and bowel dysfunction, treatment focuses on alleviating symptoms. Adherence is crucial for pharmacologic management success. We examined 73 adult’s objective adherence to rifaximin using the taxonomy for adherence. Demographic, quality of life (QOL), psychological distress, perceived stress, adverse childhood experiences (ACE), pain, and adherence data were collected. Impaired QOL, elevated psychological distress and perceived stress, and a significant number of ACE were reported at baseline. Average time to prescription initiation was 2.5 days. Once implemented, 92% missed midday dose and persisted 5 days beyond the prescribed dose. High-adherers reported lower pain levels post-rifaximin compared to low-adherers. Objective adherence was significantly lower than self-reported. Objective adherence was not predicted by above variables. Adherence to rifaximin is poor in those with IBS. Future research examining perceived barriers/facilitators toward rifaximin adherence may provide insight into patient-centered, modifiable targets for adherence interventions and improve patient-related outcomes.

show abstract

“…Persistence of continuation with the recommended dosage refers to the time between initiation and discontinuation. 2 Non-adherence can lead to increased morbidity, mortality and increased healthcare costs. 3,4 Consequently, much literature focusses on understanding factors leading to non-adherence, aiming to enhance long-term adherence.…”

Section: Introductionmentioning

confidence: 99%

Examining Adherence to Medication in Patients With Atrial Fibrillation

et al. 2020

View full text Add to dashboard Cite

show abstract

Improving medication adherence research reporting: ESPACOMP Medication Adherence Reporting Guideline (EMERGE)

Cited by 19 publications

References 9 publications

Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database

Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database

Adherence to Short-course Pharmacotherapy in Adults with Irritable Bowel Syndrome

Examining Adherence to Medication in Patients With Atrial Fibrillation

Contact Info

Product

Resources

About